Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
McKesson
Baxter
Colorcon
Johnson and Johnson
Boehringer Ingelheim

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Claims for Patent: 7,717,853

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,717,853
Title:Methods and apparatus for intracranial ultrasound delivery
Abstract: A method for delivering ultrasound energy to a patient\'s intracranial space involves forming at least one hole in the patient\'s skull, advancing at least one ultrasound delivery device at least partway through the hole(s), and transmitting ultrasound energy from the ultrasound delivery device(s). According to various embodiments, ultrasound delivery devices may be advanced into the epidural space, one or both ventricles and/or an intracerebral space of the patient\'s brain. In alternative embodiments, one or multiple holes may be formed in the skull, and any number of ultrasound delivery devices may be used. Intracranial ultrasound delivery may be used in diagnostic or therapeutic treatment of ischemic stroke, head trauma, atherosclerosis, perfusion disorders and other acute or chronic neurological conditions.
Inventor(s): Nita; Henry (Redwood Shores, CA)
Assignee:
Application Number:11/203,738
Patent Claims:1. A method for delivering ultrasound energy to a patient's intracranial space, the method comprising: forming at least one hole in the patient's skull to access a target location; advancing at least one ultrasound device having a distal portion through the hole, wherein the distal portion contains at least one transducer to allow transmission of ultrasound, and the distal portion can be moved to various locations within the intracranial space without causing damage; transmitting ultrasound energy at frequencies between 20 Khz and 10 MHz from the ultrasound delivery device for therapeutic treatment; wherein the ultrasound energy is transmitted and directed from outside a blood vessel to a blood clot in the patient's brain at the target location that resides in an intracerebral space of the patient's brain, inside of the blood vessel, to disrupt the blood clot; further comprising placing an introducer device into the at least one hole, with the at least one ultrasound delivery device advanced through the introducer device.

2. The method of claim 1, wherein advancing the ultrasound device comprises advancing a device selected from the group consisting of an ultrasound transducer and a transducer-tipped ultrasound catheter.

3. The method of claim 1, wherein the ultrasound energy is transmitted acutely.

4. The method of claim 1, wherein the ultrasound energy is transmitted chronically.

5. The method of claim 1, further comprising delivering at least one pharmacologic agent to the patient.

6. The method of claim 5, wherein the agent is selected from a group consisting of blood clot reducing agents such as tissue plasminogen activator, rTPA, Urokinease, Streptokinase, Alteplase and Desmoteplase, antiplatelet agents such as aspirin, Clopidorgel and Ticciopidine, and GIIb/IIIa inhibitors, such as Abciximab, Tirofiban and Eptifibatide.

7. The method of claim 5, wherein delivering the agent comprises using a method selected from the group consisting of intravenous, arterial and oral delivery.

8. The method of claim 1, further comprising delivering microbubbles or nanobubbles into the patient's bloodstream.

9. The method of claim 8, wherein the microbubbles or nanobubbles are delivered intravenously or arterially.

10. The method of claim 8, further comprising providing at least one pharmacologic agent to the patient.

11. The method of claim 10, wherein the microbubbles or nanobubbles and pharmacological agent are delivered in combination or sequentially.

12. The method of claim 1, further including transmitting the ultrasound energy to a blood vessel in the patient's brain to help treat atherosclerosis of the blood vessel.

13. The method of claim 1, further including transmitting the ultrasound energy to one or more blood vessels in the brain to help treat a blood perfusion abnormality in the patient's brain.

14. The method of claim 1, further providing a conductive medium which interfaces between the ultrasound transducer and the patient.

15. The method of claim 14, further including providing the conductive medium in the form of a compliant pack.

16. The method of claim 15, further providing a gel or oil inside the pack.

17. The method of claim 1, further providing a conductive medium which interfaces between the ultrasound transducer and the patient.

18. The method of claim 1, further including transmitting ultrasound energy for cerebrovascular diagnostics.

19. The method of claim 1, further including transmitting ultrasound energy for cerebrovascular diagnostics and therapeutic treatment.

Details for Patent 7,717,853

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 001 1987-11-13   See Pricing 2036-04-30 RX search
Genentech ACTIVASE alteplase VIAL; SINGLE-USE 103172 002 1987-11-13   See Pricing 2036-04-30 RX search
Genentech CATHFLO ACTIVASE alteplase VIAL 103172 003 1987-11-13   See Pricing 2036-04-30 RX search
Centocor Inc REOPRO abciximab INJECTABLE; INJECTION 103575 001 1994-12-22   See Pricing 2036-04-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 7,717,853

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKinsey
Harvard Business School
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.